ENZN — Enzon Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $7.42m
- -$39.44m
- $0.03m
- 70
- 52
- 33
- 51
Annual balance sheet for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 48.1 | 47.6 | 47 | 47 | 46.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.031 | 0.028 | 0 | — | — |
| Total Other Current Assets | |||||
| Total Current Assets | 48.2 | 47.8 | 47.4 | 47.3 | 47.2 |
| Other Long Term Assets | |||||
| Total Assets | 48.2 | 47.8 | 47.6 | 47.7 | 47.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.412 | 0.403 | 1.7 | 1.71 | 1.68 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.412 | 0.403 | 1.7 | 1.71 | 1.68 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 47.8 | 47.4 | 45.9 | 46 | 45.5 |
| Total Liabilities & Shareholders' Equity | 48.2 | 47.8 | 47.6 | 47.7 | 47.2 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |